1、This presentation contains certain forward-looking statements.These forward-looking statements may be identified by words such as believes,expects,anticipates,projects,intends,should,seeks,estimates,future or similar expressions or by discussion of,among other things,strategy,goals,plans or intentio

2、ns.Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation,among others:1 pricing and product initiatives of competitors;2 legislative and regulatory developments and economic conditions;3 delay or

3、inability in obtaining regulatory approvals or bringing products to market;4 fluctuations in currency exchange rates and general financial market conditions;5 uncertainties in the discovery,development or marketing of new products or new uses of existing products,including without limitation negativ

4、e results of clinical trials or research projects,unexpected side-effects of pipeline or marketed products;6 increased government pricing pressures;7 interruptions in production;8 loss of or inability to obtain adequate protection for intellectual property rights;9 litigation;10 loss of key executiv

5、es or other employees;and11 adverse publicity and news coverage.Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roches earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the his

6、torical published earnings or earnings per share of Roche.For marketed products discussed in this presentation,please see full prescribing information on our website All mentioned trademarks are legally protected.RocheHY 2025 resultsBasel,24 July 2025GroupThomas SchineckerChief Executive Officer Per